Clinical Trial Search

Primary: P16 Evaluation in Ovarian Germ Cell Tumors — 7; 4; 0; 6 units on a scale — p=0.001

Primary: Tumor Marker CA125 — 189; 4 U/mL — p=<0.001

Primary: Dose Limiting Toxicity (DLT) — 8; 23; 2 participants

Primary: Acute Toxicity Rate — 6 percentage of participants

Primary: Overall Survival at 2 Years and 5 Years — 93; 85 percentage of participants

Primary: Proportion of Patients With Completion of 4 Cycles of CT + GB — 0.7826 proportion of patients

Primary: Patients With Changes in Bone Marrow Assessed Through Images — 0; 4 Participants

Primary: Mean Doses Given — 93.9; 63.2; 58.63 Gy

Primary: Correlation Between Circulating Levels of These Markers and Demographic Characteristics. — 39; 42; 11; 8 Participants — p=0.026

Primary: Number of Patients With Objective Tumor Response Rate (Complete Response [CR] or Partial Response [PR]) Using RECIST Version 1.0 — 2; 0 participants

Primary: Overall Survival — 2.14; 2.00 years

Primary: Number of Participants Experiencing Serious Adverse Events and Non-serious Adverse Events

Primary: Patient Reported Satisfaction — 54; 55 satisfaction score at baseline

Primary: Percentage of Subjects With Reduction of Uterine Bleeding at Week 13 Visit Defined as Pictorial Blood-loss Assessment Chart (PBAC) Score < 75 at End-of-treatment Visit…

Primary: Number of Participants With Overall Response — 8 participants

Primary: Change in Tumor Immune Infiltrates as Measured by PD-L1 Modified H-Score — 13.2 score on a scale

Primary: Successful Removal of the Uterus Without Conversion to Another Technique — 35; 35 Participants — p=0.0221

Primary: Chemotherapy Completion Rate — 100 percentage of participants

Primary: Hospital Stay — 3.0; 3.0 Days — p=0.36

Primary: Tumor Response — 16.7 percentage of patients

Primary: Negative Predictive Value of Sentinel Lymph Node Prediction of Metastatic Disease — 98.8 percentage of patients

Primary: Maximum Tolerated Dose of Integrated Boost Radiation Therapy, Administered With IMRT Technique With Concurrent Chemotherapy (Cisplatin). — 70 Gray (Gy)

Primary: Dose Limiting Toxicity (DLT) — 0; 0; 0 Participants

Primary: Safety and Tolerability (Adverse Event Reported Per CTCAE v5) — 6; 0; 6; 6 Participants

Primary: Progression-free Survival (PFS) > 6 Months — 17.8 percentage of participants

Primary: Overall Response Rate (ORR) — 0; 0 participants

Primary: Progression-Free Survival — 64.7 percentage of patients

Primary: Number of Participants According to the Management Plan in Patients With Diffuse TGCT (d-TGCT) — 94; NA; NA; NA Participants

Primary: Operation Time — 146.1; 124.6 seconds

Primary: Number of Sentinel Lymph Nodes (SLNs) Identified by Lymphosonography as Well as Blue Dye or Positron Emission Tomography (PET)-Computed Tomography (CT) — 17 sentinel…